Diabetes and Byetta

How Diabetes Topics in the News Can Start to Feel Like a Game of “Telephone”

A recent Wall Street Journal article shows once again how misinformation about diabetes-related topics can be spread by even the most expert journalists.

3 comments - Oct 27, 2008 -

news

Amylin’s Woes Mount, Thanks to FDA Actions

The stock of Byetta manufacturer Amylin Pharmaceuticals has lost more than half of its value over the past eight weeks, thanks to FDA concerns that the type 2 treatment may be connected with the deaths from acute pancreatitis of six Byetta users. Although the FDA has not proven a direct association between fatal pancreatitis and the use of Byetta, Amylin's stock has fallen nevertheless.

0 comments - Oct 13, 2008 -

news

Good News for Byetta (Exenatide): Canadian Study Reports Once-Weekly Dose Is Better at BG Control Than Twice Daily

A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.

3 comments - Sep 11, 2008 -

blog

Byetta Takes a Beating as Feds Question Its Safety; Defender Chides FDA for Bureaucracy and Bad Science

Byetta has had a tough past few days. A lawsuit by a Virginia man alleges that the drug caused his life-threatening bout of severe pancreatitis, and there are rumblings from the U.S. Food and Drug Administration that it may force Byetta's makers to attach a "black box" warning to its container and packaging-a stern, highlighted caution about potentially dangerous, even fatal, side effects.

19 comments - Aug 28, 2008 -

news

Byetta Breaks the Piggy Bank

San Diego-based Amylin Pharmaceuticals, Inc., posted a second-quarter loss of $64.8 million, or 47 cents per share. This compares to a 2007 second-quarter loss of 45 million, or 34 cents a share.

Comments 1 comment - Jul 31, 2008 -

news

Can Byetta Be a Standalone Treatment for Type 2?

Since its introduction in 2005, Byetta has become “the talk of the town” as one of the most powerful, yet benign, diabetes drugs of the 21st century.

4 comments - Apr 2, 2008 -

The Beneficial Effects of Byetta: An Interview With Amylin

SK: We’re joined on our show by Craig Eberhard, vice president of sales at Amylin Pharmaceuticals. Hey, Craig, thanks for coming on the show. Amylin has one of the most innovative products that I’ve heard of in years. It’s called Byetta.

8 comments - Feb 1, 2008 -

blog

Byetta Dusts Insulin In Year-Long Trial

In a recent randomized study, 69 people with type 2 diabetes who were already taking metformin were given either Byetta or Lantus for a full year. When the results were in, Byetta came out ahead on several fronts.

10 comments - Dec 11, 2007 -

news

Warning About Byetta and Pancreatitis

The FDA has received thirty reports of acute pancreatitis (rapid-onset inflammation of the pancreas) in type 2 patients taking Byetta. Twenty-seven of the thirty patients had one or more risk factors for acute pancreatitis, such as gallstones or alcohol use.

Comments 1 comment - Nov 5, 2007 -

Once-Weekly Byetta LAR (exenatide long-acting release): So Far, It Works

It's a fact that Byetta reduces A1c's, post-meal and fasting glucose levels, and weight in people with type 2 diabetes. The drawback is that it's another injection twice a day. In response, Amylin, the maker of Byetta, has developed exenatide LAR, a form of Byetta that is injected only once a week.

0 comments - Jul 13, 2007 -

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer